Cotta Claudiu V, Leventaki Vasiliki, Atsaves Vassilis, Vidaki Athina, Schlette Ellen, Jones Dan, Medeiros L Jeffrey, Rassidakis George Z
Department of Hematopathology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.
Cancer. 2008 Feb 1;112(3):552-61. doi: 10.1002/cncr.23196.
Inhibitor of DNA binding 2 (Id2), a helix-loop-helix protein of the inhibitor of differentiation (ID) family, is involved in hematopoiesis, mainly through interaction with the E-family of transcription factors. Recent studies have shown that Id2 is overexpressed in some types of B-cell lymphoma, including classical Hodgkin lymphoma. The authors of the current study hypothesized that Id2 also is overexpressed in T-cell lymphomas.
By using reverse-transcriptase polymerase chain reaction (RT-PCR) and Western blot analyses, high Id2 messenger RNA (mRNA) and protein levels, respectively, were detected in all 4 T-cell anaplastic large cell lymphoma (ALCL) cell lines that were tested.
Immunohistochemistry results indicated that Id2 was expressed strongly in 21 of 27 (78%) ALCL tumors (79% anaplastic lymphoma kinase [ALK]-negative and 75% ALK-positive), in 5 of 10 (50%) extranodal natural killer/T (NK/T)-cell lymphomas of the nasal type, in 2 of 8 (25%) cutaneous ALCLs, in 2 of 9 (22%) enteropathy type T-cell lymphomas, in 1 of 5 (20%) peripheral T-cell lymphomas not otherwise specified, and in 1 of 8 (13%) T-cell prolymphocytic leukemias. Other types of T-cell lymphoma were negative for Id2. Because it is known that myc is expressed in ALCL, myc was inhibited selectively in 2 ALCL cell lines, resulting in a concentration-dependent decrease in Id2 mRNA and protein levels. Conversely, forced expression of myc in HEK 293T cells using an myc/green fluorescent protein adenoviral vector resulted in Id2 up-regulation.
Taken together, the current data suggest that Id2 commonly is overexpressed in highly proliferative T-cell lymphomas, and its expression may result from transcriptional activation of myc in these tumors.
DNA结合抑制因子2(Id2)是分化抑制因子(ID)家族的一种螺旋-环-螺旋蛋白,主要通过与E族转录因子相互作用参与造血过程。最近的研究表明,Id2在某些类型的B细胞淋巴瘤中过度表达,包括经典型霍奇金淋巴瘤。本研究的作者推测Id2在T细胞淋巴瘤中也过度表达。
通过逆转录聚合酶链反应(RT-PCR)和蛋白质免疫印迹分析,在所有检测的4种T细胞间变性大细胞淋巴瘤(ALCL)细胞系中分别检测到高水平的Id2信使核糖核酸(mRNA)和蛋白质。
免疫组织化学结果表明,Id2在27例ALCL肿瘤中的21例(78%)中强烈表达(间变性淋巴瘤激酶[ALK]阴性的占79%,ALK阳性的占75%),在10例鼻型结外自然杀伤/T(NK/T)细胞淋巴瘤中的5例(50%)中表达,在8例皮肤ALCL中的2例(25%)中表达,在9例肠病型T细胞淋巴瘤中的2例(22%)中表达,在5例未另行特指的外周T细胞淋巴瘤中的1例(20%)中表达,在8例T细胞原淋巴细胞白血病中的1例(13%)中表达。其他类型的T细胞淋巴瘤Id2呈阴性。由于已知myc在ALCL中表达,在2种ALCL细胞系中选择性抑制myc,导致Id2 mRNA和蛋白质水平呈浓度依赖性下降。相反,使用myc/绿色荧光蛋白腺病毒载体在人胚肾293T细胞中强制表达myc导致Id2上调。
综上所述,目前的数据表明Id2在高度增殖性T细胞淋巴瘤中普遍过度表达,其表达可能是由于这些肿瘤中myc的转录激活所致。